Skip to main content
OpenTrials
Completed

NCT Number: NCT02980679

A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need Surgery

A 99mTc Pertechnetate (G-PERT) scan is a nuclear medicine test that can create an image of the thyroid gland and other organs. G-PERT is approved by Health Canada for the direct imaging and measurement of thyroid uptake.

Doctors and researchers at the University of Alberta have developed a new method of producing 99mTc Pertechnetate (called CTC). It is made in a cyclotron at the Medical Isotope and Cyclotron Facility (MICF) at the University of Alberta, Edmonton, Alberta. This new production method will provide another source of 99mTc Pertechnetate. The aim of this study is to confirm that CTC is safe and can be used interchangeably with G-PERT.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thyroid Gland Diseases Endocrine System Diseases Thyroid Diseases

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

About this study

The clinical trial will be a Phase III, prospective, crossover, image interpretation blinded, single site study. All subjects will receive Tc-99m pertechnetate (one CTC and one G-PERT administration separated by at least 48 hours) and subsequently be imaged for thyroid uptake and whole body biodistribution. The order of the scans will be randomized. The thyroid image will be interpreted for uptake / no uptake in the thyroid, and the whole body biodistribution image will be interpreted for uptake / no uptake in selected anatomical sites. Interpretation of thyroid imaging results will be compared with other clinical findings (such as pre-surgical ultrasound, fine needle aspirate, and post-surgical pathology results, when available). All imaging assessments will be conducted by 1 blinded Nuclear Medicine physician. A safety evaluation will be conducted on all subjects receiving CTC, consisting of vital signs, haematology and SMA-12 serum biochemistry profile (pre-injection and post-imaging), and, for both CTC and G-PERT, an adverse event assessment (until the subject leaves the Nuclear Medicine department) after each administration.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female ≥ 18 years of age and < 80 years of age.
  • Have a proven or suspected thyroid pathology that requires surgery by standard clinical criteria.
  • Able and willing to follow instructions and comply with the protocol.
  • Provide written informed consent prior to participation in the study.

Exclusion criteria

  • Nursing or pregnant females.

Treatment and study plan

CTC

Drug

After injection of CTC, a whole body and thyroid scan will be performed.

Other names: Cyclotron-produced technetium

G-PERT

Drug

After injection of G-PERT, a whole body and thyroid scan will be performed.

Other names: Generator-produced technetium

Primary outcomes

  1. Clinical Comparability of CTC with G-PERT

    Time frame: up to 1 year

    The primary efficacy endpoint is the clinical comparability of CTC with G-PERT consisting of a combination of the following results:

    • A thyroid image, assessed for uptake or no uptake in the thyroid.
    • A whole body biodistribution study, assessed for uptake or no uptake in selected anatomical areas.

Secondary outcomes

  1. Change in vital signs after CTC injection

    Time frame: Before CTC injection and after CTC scan (within ~30 min)

    Vital signs are measured before injection of CTC and after CTC scan and changes will be summarized.

  2. Changes in haematology / SMA-12 serum biochemistry after CTC injection

    Time frame: Before CTC injection and after CTC scan (within ~30 min)

    A blood sample is drawn before injection of CTC and after CTC scan. The haematology and SMA-12 serum biochemistry parameters will be recorded and all changes will be summarized.

  3. Number of participants with adverse events

    Time frame: up to 1 year

    Subjects will be monitored for adverse events after CTC and G-PERT scans while in the Nuclear Medicine Department. All adverse events observed or reported will be recorded and assessed.

  4. Correlation of CTC with other clinical findings

    Time frame: up to 1 year

    Correlation of thyroid images with other clinical findings (such as pre-surgical ultrasound, FNA, and post-surgical pathology results, when available).

  5. CTC diagnostic outcomes and parameters

    Time frame: up to 1 year

    Calculation of diagnostic outcomes (TP, TN, FP, FN) and the corresponding diagnostic parameters (sensitivity, specificity, accuracy).

  6. Overall clinical comparability of CTC with G-PERT

    Time frame: up to 1 year

    The overall clinical comparability of CTC with G-PERT using diagnostic outcomes (True Positive, True Negative, False Positive, False Negative) to determine the corresponding diagnostic parameters (sensitivity, specificity, accuracy).

Sponsors and collaborators

Lead sponsor

University of Alberta

Other

Registry information

Official study title

A Pivotal Phase III Study of Cyclotron-produced Tc-99m Pertechnetate (CTC) Compared to Generator-produced Tc-99m Pertechnetate (G-PERT) in Subjects With Thyroid Disorders

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Dec 2, 2016
Registry last updated
Apr 11, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.